Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori

Figures & data

Table 1 Baseline Demographics, Comorbidities and Methods of Helicobacter pylori Diagnosis in the Study Population

Characteristic	CLA Triple Therapy (N=97)	LEVO Triple Therapy (N=63)	Bismuth Quadruple Therapy (N=17)	P-value
Age, years*	52.53±13.59	50.41±14.89	56.82±15.03	0.243
Gender, N (%)				0.670
Male	31 (31.9)	22 (34.9)	4(23.5)
Female	66 (68.1)	41 (65.1)	13 (76.5)
BMI, N (%)				0.316
<30	50 (51.5)	40 (63.5)	9 (52.9)
>30	47 (48.5)	23 (36.5)	8 (47.1)
Race, N (%)				0.001
Asian	1 (1.1)	3 (4.76)	0 (0)
African American	26 (26.8)	20 (31.7)	4 (23.5)
Caucasian	21 (21.6)	3 (4.76)	4 (23.5)
Hispanic	49 (50.5)	37 (58.7)	9 (53)
Hypertension, N (%)	38(39.2)	25 (39.7)	10 (58.9)	0.301
Diabetes mellitus, N (%)	22 (22.7)	20 (31.7)	7 (41.2)	0.194
Smoker, N (%)	14 (14.4)	8 (12.7)	3 (17.6)	0.866
Diagnostic modality				0.001
Upper GI Endoscopy (EGD)	96	43	16
H. pylori stool antigen	1	18	1
Urea breath test	0	2	0
Histological changes
Lymphoid Follicles	21	21	6	0.881
Foveolar hyperplasia	14	7	3	0.852
Intestinal metaplasia	10	3	2	0.592

Note: * Mean±SD.


Table 2 Eradication Rates of Various Therapies

	CLA Triple Therapy (N=97)	LEVO Triple Therapy (N=63)	Bismuth Quadruple Therapy (N=17)	P-value
Successful treatment – Overall (%)	76 (78.3)	31 (49.2)	7 (41.1)	0.001
Gastric ulcer on Endoscopy (%)	24 (24.7)	4 (6.3)	3 (17.6)	0.001
Successful treatment in patients with gastric ulcer (%)	18 (75)	3 (75)	0 (0)	0.031

Table 3 Logistic Regression Analysis of Factors Associated with Successful Helicobacter pylori Eradication

Variable	Odds Ratio	95% CI	P-value
Age	1.006	0.979–1.034	0.669
Gender	0.849	0.429–1.680	0.638
Obesity (BMI>30)	0.854	0.462–1.581	0.616
Race	1.019	0.733–1.415	0.911
Hypertension	0.751	0.343–1.647	0.475
Diabetes mellitus	1.372	0.626–3.007	0.430
Smoker	1.918	0.797–4.617	0.146
Ulcer on EGD	0.941	0.405–2.186	0.888
Histological changes
Lymphoid Follicles	1.403	0.722–2.724	0.318
Foveolar hyperplasia	1.717	0.628–4.697	0.292
Intestinal metaplasia	1.289	0.376–4.419	0.686

Table 4 Efficacy of Second Therapy in Patients Who Failed Their First Therapy

	CLA Triple Therapy	LEVO Triple Therapy	Bismuth Quadruple Therapy	P-value
Patients who underwent second therapy	0	14	19	0.001
Successful second treatment (%)	0 (0)	5 (35.7)	11 (57.9)	0.208
Combined patients undergoing therapy (first and second treatments)	97	77	36	0.001
Overall successful treatment (%)	76 (78.3)	36 (46.7)	18 (50)	0.001

Table 5 Logistic Regression Analysis Evaluating Factors Associated with Successful Second Therapy

Variable	Odds Ratio	95% CI	P-value
Age	1.002	0.932–1.076	0.967
Gender	1.246	0.147–10.558	0.840
Hypertension	1.517	0.174–13.240	0.706
Diabetes mellitus	1.065	0.125–9.086	0.954
Smoker	0.183	0.015–2.256	0.185